Compare INVE & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INVE | CUE |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.1M | 233.5M |
| IPO Year | 1997 | 2017 |
| Metric | INVE | CUE |
|---|---|---|
| Price | $2.39 | $25.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $3.55 | ★ $88.00 |
| AVG Volume (30 Days) | 107.2K | ★ 353.1K |
| Earning Date | 11-09-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $60,219,000.00 | $27,466,000.00 |
| Revenue This Year | $21.08 | N/A |
| Revenue Next Year | $16.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.21 | ★ 195.75 |
| 52 Week Low | $2.32 | $0.17 |
| 52 Week High | $5.30 | $45.50 |
| Indicator | INVE | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 38.97 | 42.64 |
| Support Level | $2.32 | $23.51 |
| Resistance Level | $3.03 | $33.11 |
| Average True Range (ATR) | 0.09 | 4.91 |
| MACD | -0.01 | -0.83 |
| Stochastic Oscillator | 30.38 | 11.41 |
Identiv Inc develops specialty radio-frequency identification (RFID) and Internet of Things It (IoT) solutions that address customers' challenges and create new opportunities for them through the digitization and enhanced connectivity to the IoT. It designs, produces, and sells RFID and Bluetooth Low Energy (BLE) enabled devices, RFID inlays, tags, and labels that can be applied or incorporated into physical objects, providing them with a digital identity and the ability for customers to track, monitor, authenticate, and engage with consumers. Its IoT Business segment develops, manufactures, and supplies specialty IoT solutions tailored for the healthcare, logistics, smart packaging industries and other high-value end markets.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.